Company file

Identity

ACOBIOM

ACOBIOM is a biotech company specialized in the discovery of new biomarkers and the development of diagnostics tests focused on precision medicine applications (oncology). Acobiom notably developed “GemciTest™,” a non invasive blood test, which is the 1st diagnostic for the prediction of treatment response in pancreatic cancer. Acobiom developed many capabilities in the bioinformatics analysis of gene expression and in the identification of RNA biomarkers that are specific to the studied pathology or biological question. Our scientific team is using a unique and patented technological Omic platform based on New Generation Sequencing (NGS) and real-time PCR associated with proprietary bioinformatics and biostatistics tools.

Acobiom is offering both: - Collaboration for the identification/validation of biomarkers involved in precision medicine applications. . - Services for genomic and pharmacogenomic biomarkers analyses dedicated to research and diagnosis applications, as well as for helping to develop new treatments:clinical trials, polymorphic drug target and disposition genes, drug exposure and clinical response variability, genotype-specific dosing...